Compare Novo Nordisk A/S (NVO) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs TeraWulf Inc — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while TeraWulf Inc trades at $20.04 (market cap $9.35B). The key difference: Novo Nordisk A/S is far larger — about 23.6× TeraWulf Inc's market cap, and Novo Nordisk A/S pays a 3.63% dividend while TeraWulf Inc pays none. Which is the better fit depends on your goals.
| NVO | WULF | |
|---|---|---|
Market Cap | $220.53B | $9.35B |
Sector | Health | Technology |
52-Week High | $71.70 | $28.98 |
52-Week Low | $35.29 | $4.76 |
Enterprise Value | $239.49B | $12.03B |
Dividend Yield | 3.63% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
